Neurocrine (NBIX) initiated a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator, an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder, or MDD. Positive topline data for the Phase 2 SAVITRI study of osavampator in adult subjects with MDD were announced in April 2024. The Phase 2 SAVITRI study with osavampator met its primary and secondary endpoints, and was generally well tolerated. Neurocrine received an exclusive license to osavampator from Takeda Pharmaceutical for all indications in all territories worldwide except Japan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Closing Bell Movers: Graco down 5% as earnings, guidance miss
- Neurocrine Amends License Agreement with Takeda
- Neurocrine announces amendment to collaboration with Takeda
- No major surprises from Neurocrine presentation, says JPMorgan
- Trump Trade: New administration to invest $20B to build data centers